市場調查報告書

全球冠狀病毒感染(COVID-19)診斷市場:機會分析和行業預測(2020-2022)

Covid-19 Diagnostics Market by Product, Technology, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2022

出版商 Allied Market Research 商品編碼 948575
出版日期 內容資訊 英文 275 Pages
商品交期: 2-3個工作天內
價格
全球冠狀病毒感染(COVID-19)診斷市場:機會分析和行業預測(2020-2022) Covid-19 Diagnostics Market by Product, Technology, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2022
出版日期: 2020年05月01日內容資訊: 英文 275 Pages
簡介

新的冠狀病毒感染(COVID-19)診斷的全球市場預計到2020年底將達到7.8億美元。

全球COVID-19發病率急劇上升,死亡率上升是市場增長的主要動力。此外,技術開發和各種公司推出的各種測試套件正推動著市場的發展。但是,預計發展中國家缺乏診斷試劑盒會阻礙市場的增長。預計生長因子的影響將超過抑制因子的影響。因此,市場有望快速增長。

本報告涵蓋全球新市場冠狀病毒感染性疾病(COVID-19)診斷市場,包括促進市場增長,市場機會,市場趨勢,市場規模趨勢和預測,技術/產品/最終用戶/地區/的因素它包括按主要國家/地區,競爭環境和主要公司簡介進行的詳細分析。

內容

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 波特的五力分析
  • 市場動態
    • 生長因子
      • COVID-19感染的發生率顯著增加
      • 沒有可用的特定藥物/疫苗
    • 抑制因素
      • 沒有COVID-19診斷套件的要點
    • 市場機會
      • 新興國家的各種增長機會

第4章按技術分類的全球COVID-19診斷市場

  • 概述
    • 批准的COVID-19診斷產品
    • 市場規模和技術預測
  • 分子測定
    • 主要市場趨勢和機遇
    • 市場規模和地區預測
  • 免疫測定/血清學
    • 主要市場趨勢和機遇
    • 市場規模和地區預測

第5章COVID-19診斷市場(按產品)

  • 概述
    • 市場規模和產品預測
  • PCR試劑盒
    • 市場規模和地區預測
  • 免疫分析盒/條
    • 市場規模和地區預測
  • 護理點(POC)檢查
    • 市場規模和地區預測

第6章按最終用戶劃分的全球COVID-19診斷市場

  • 概述
    • 最終用戶的市場規模和預測
  • 醫院
    • 市場規模和地區預測
  • 診斷實驗室
    • 市場規模和地區預測
  • 內科診所和急診診所
    • 市場規模和地區預測

按地區劃分的第7章COVID-19診斷市場

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢和機遇
    • 市場規模和國家預測
      • 美國市場規模和技術預測
      • 美國市場規模和產品預測
      • 美國市場規模和最終用戶的預測
      • 加拿大市場規模和技術預測
      • 加拿大市場規模和產品預測
      • 加拿大。市場規模和最終用戶的預測
      • 墨西哥市場規模和技術預測
      • 墨西哥市場規模和產品預測
      • 墨西哥的市場規模和最終用戶的預測
  • 歐洲
    • 主要市場趨勢
    • 市場規模和國家預測
      • 法國市場規模和技術預測
      • 法國市場規模和產品預測
      • 法國市場規模和最終用戶的預測
      • 英國市場規模和技術預測
      • 英國市場規模和產品預測
      • 英國市場規模和最終用戶的預測
      • 德國市場規模和技術預測
      • 德國市場規模和產品預測
      • 德國市場規模和最終用戶的預測
      • 西班牙市場規模和技術預測
      • 西班牙市場規模和產品預測
      • 西班牙市場規模和最終用戶的預測
      • 意大利市場規模和技術預測
      • 意大利市場規模和產品預測
      • 意大利市場規模和最終用戶的預測
      • 奧地利市場規模和技術預測
      • 奧地利市場規模和產品預測
      • 奧地利市場規模和最終用戶的預測
      • 愛沙尼亞市場規模和技術預測
      • 愛沙尼亞市場規模和按產品預測
      • 愛沙尼亞市場規模和最終用戶的預測
      • 捷克共和國市場規模和技術預測
      • 捷克共和國市場規模和產品預測
      • 捷克共和國市場規模和最終用戶的預測
      • 其他歐洲市場規模和技術預測
      • 其他歐洲市場規模和產品預測
      • 其他歐洲市場規模和最終用戶的預測
  • 亞太地區
    • 主要市場趨勢和機遇
    • 市場規模和國家預測
      • 日本市場規模和技術預測
      • 日本市場規模和產品預測
      • 日本市場規模和最終用戶的預測
      • 中國市場規模及技術預測
      • 中國市場規模和產品預測
      • 中國市場規模和最終用戶的預測
      • 印度市場規模和技術預測
      • 印度市場規模和產品預測
      • 印度市場規模和最終用戶的預測
      • 澳大利亞市場規模和技術預測
      • 澳大利亞市場規模和產品預測
      • 澳大利亞市場規模和最終用戶的預測
      • 韓國市場規模和技術預測
      • 韓國市場規模和產品預測
      • 韓國市場規模和最終用戶的預測
      • 泰國市場規模及技術預測
      • 泰國市場規模和產品預測
      • 泰國市場規模和最終用戶的預測
      • 馬來西亞市場規模和技術預測
      • 馬來西亞市場規模和產品預測
      • 馬來西亞市場規模和最終用戶的預測
      • 其他亞太市場規模和按技術預測
      • 其他亞太市場規模和產品預測
      • 其他亞太市場規模和最終用戶的預測
    • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 市場規模和國家預測
      • 巴西市場規模和技術預測
      • 巴西市場規模和產品預測
      • 巴西最終用戶的市場規模和預測
      • 南非市場規模和技術預測
      • 南非市場規模和產品預測
      • 南非市場規模和最終用戶的預測
      • 沙特阿拉伯市場規模和技術預測
      • 沙特阿拉伯市場規模和按產品預測
      • 沙特阿拉伯的市場規模和最終用戶的預測
      • 以色列市場規模和技術預測
      • 以色列市場規模和產品預測
      • 以色列市場規模和最終用戶的預測
      • 其他LAMEA市場規模和技術預測
      • 其他LAMEA市場規模和產品預測
      • 其他LAMEA市場規模和最終用戶的預測

第8章公司簡介

  • Abbott Laboratories
  • Cellex Incorporated
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Laboratory Corp of America Holdings
  • Mylab Discovery Solutions Pvt. Ltd.
  • Quest Diagnostics Incorporated
  • Seegene Inc.
  • Thermo Fisher Scientific, Inc.
目錄
Product Code: A06114

Title:
Covid-19 Diagnostics Market by Product (PCR Kits, POC Kits and Immunoassay), Technology (Molecular and Immunoassay), and End User (Hospitals, Physician's office & urgent care clinics and Diagnostic Labs): Global Opportunity Analysis and Industry Forecast, 2020-2022.

The global covid-19 diagnostics market size is anticipated to reach $780 million till the end of 2020. Covid-19 is an infectious disease caused by a newly discovered coronavirus with a nomenclature Sars Cov 2.The virus strain shows significant similarity with an earlier detected virus, Sars Cov. The virus outbreak started from Wuhan city of China and is now spread across 210 countries and territories around the world and 2 international conveyances, as per Worldometer data.

Significant increase in the incidences of covid-19 across the globe and rise in mortality rates due to the outbreak are the major factors that drive the market growth. Moreover, technological developments and introduction of various test kits by companies worldwide propels the market growth. However, dearth of diagnosis kits in developing economies is anticipated to hamper the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a fast pace.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current Covid-19 diagnostics market trends and forecast estimations from 2020 to 2022, which assists to identify the prevailing market opportunities.

An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.

A comprehensive analysis of factors that drive and restrain the covid-19 market growth is provided.

The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2022, in terms of value.

An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

Key players within the market are profiled in this report and their strategies are analyzed thoroughly, which help in understanding competitive outlook.

KEY MARKET SEGMENTS

By Product

PCR Kits

POC Kits

Immuno Assay

By Technology

  • Molecular
  • Immunoassay

By End User

  • Hospitals
  • Physician's office and urgent care clinics
  • Diagnostic Labs

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Estonia
  • Austria
  • Czech Republic
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Australia
  • Japan
  • South Korea
  • Thailand
  • Malaysia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Israel
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • F. Hoffmann-La Roche AG
  • Seegene Inc.
  • Cepheid
  • Mylab Lifesolutions Pvt. Ltd.
  • SureScreen Diagnostics Ltd
  • Thermo Fisher Scientific
  • Genematrix
  • Robert Bosch GmbH
  • Cellex

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Research methodology
    • 1.3.1.Secondary research
    • 1.3.2.Primary research
    • 1.3.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Porter's five forces analysis
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Significant increase in the incidence of covid-19 infection
      • 3.3.1.2.Unavailability of specific medicine/ vaccine
    • 3.3.2.Restraints
      • 3.3.2.1.Lack of covid-19 diagnosis kits
    • 3.3.3.Opportunities
      • 3.3.3.1.Various growth opportunities in emerging economies

CHAPTER 4:GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 4.1.Overview
    • 4.1.1.Approved covid-19 Diagnostic Products
    • 4.1.2.Market size and forecast, By Technology
  • 4.2.Molecular Assay
    • 4.2.1.Key market trends and opportunities
    • 4.2.2.Market size and forecast, by region
  • 4.3.Immunoassay/Serology
    • 4.3.1.Key market trends and opportunities
    • 4.3.2.Market size and forecast, by region

CHAPTER 5:COVID-19 DIAGNOSTICS MARKET, BY PRODUCT

  • 5.1.Overview
    • 5.1.1.Market size and forecast, by product
  • 5.2.PCR Kits
    • 5.2.1.Market size and forecast, by region
  • 5.3.Immunoassay Cassettes/Strips
    • 5.3.1.Market size and forecast, by region
  • 5.4.POC (Point of care) test
    • 5.4.1.Market size and forecast, by region

CHAPTER 6:GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast, by end user
  • 6.2.Hospitals
    • 6.2.1.Market size and forecast, by region
  • 6.3.Diagnostics Laboratory
    • 6.3.1.Market size and forecast, by region
  • 6.4.Physician's office and urgent care clinics
    • 6.4.1.Market size and forecast, by region

CHAPTER 7:COVID-19 DIAGNOSTICS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S. market size and forecast, By Technology
      • 7.2.2.2.U.S. market size and forecast, by product
      • 7.2.2.3.U.S. market size and forecast, by end user
      • 7.2.2.4.Canada market size and forecast, By Technology
      • 7.2.2.5.Canada market size and forecast, by product
      • 7.2.2.6.Canada. market size and forecast, by end user
      • 7.2.2.7.Mexico market size and forecast, By Technology
      • 7.2.2.8.Mexico market size and forecast, by product
      • 7.2.2.9.Mexico. market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.France market size and forecast, By Technology
      • 7.3.2.2.France market size and forecast, by product
      • 7.3.2.3.France. market size and forecast, by end user
      • 7.3.2.4.UK market size and forecast, By Technology
      • 7.3.2.5.UK market size and forecast, by product
      • 7.3.2.6.UK. market size and forecast, by end user
      • 7.3.2.7.Germany market size and forecast, By Technology
      • 7.3.2.8.Germany market size and forecast, by product
      • 7.3.2.9.Germany market size and forecast, by end user
      • 7.3.2.10.Spain market size and forecast, By Technology
      • 7.3.2.11.Spain market size and forecast, by product
      • 7.3.2.12.Spain market size and forecast, by end user
      • 7.3.2.13.Italy market size and forecast, By Technology
      • 7.3.2.14.Italy market size and forecast, by product
      • 7.3.2.15.Italy market size and forecast, by end user
      • 7.3.2.16.Austria market size and forecast, by technology
      • 7.3.2.17.Austria market size and forecast, by product
      • 7.3.2.18.Austria market size and forecast, by end user
      • 7.3.2.19.Estonia market size and forecast, by technology
      • 7.3.2.20.Estonia market size and forecast, by product
      • 7.3.2.21.Estonia market size and forecast, by end user
      • 7.3.2.22.Czech Republic market size and forecast, by technology
      • 7.3.2.23.Czech Republic market size and forecast, by product
      • 7.3.2.24.Czech Republic market size and forecast, by end user
      • 7.3.2.25.Rest of Europe market size and forecast, By Technology
      • 7.3.2.26.Rest of Europe market size and forecast, by product
      • 7.3.2.27.Rest of Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan market size and forecast, by technology
      • 7.4.2.2.Japan market size and forecast, by product
      • 7.4.2.3.Japan market size and forecast, by end user
      • 7.4.2.4.China market size and forecast, by technology
      • 7.4.2.5.China market size and forecast, by product
      • 7.4.2.6.China market size and forecast, by end user
      • 7.4.2.7.India market size and forecast, by technology
      • 7.4.2.8.India market size and forecast, by product
      • 7.4.2.9.India market size and forecast, by end user
      • 7.4.2.10.Australia market size and forecast, by technology
      • 7.4.2.11.Australia market size and forecast, by product
      • 7.4.2.12.Australia market size and forecast, by end user
      • 7.4.2.13.South Korea market size and forecast, by technology
      • 7.4.2.14.South Korea market size and forecast, by product
      • 7.4.2.15.South Korea market size and forecast, by end user
      • 7.4.2.16.Thailand market size and forecast, by technology
      • 7.4.2.17.Thailand market size and forecast, by product
      • 7.4.2.18.Thailand market size and forecast, by end user
      • 7.4.2.19.Malaysia market size and forecast, by technology
      • 7.4.2.20.Malaysia market size and forecast, by product
      • 7.4.2.21.Malaysia market size and forecast, by end user
      • 7.4.2.22.Rest of Asia-Pacific market size and forecast, by technology
      • 7.4.2.23.Rest of Asia-Pacific market size and forecast, by product
      • 7.4.2.24.Rest of Asia-Pacific market size and forecast, by end user
    • 7.4.3.LAMEA
    • 7.4.4.Key market trends and opportunities
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Brazil market size and forecast, by technology
      • 7.4.5.2.Brazil market size and forecast, by product
      • 7.4.5.3.Brazil market size and forecast, by end user
      • 7.4.5.4.South Africa market size and forecast, by technology
      • 7.4.5.5.South Africa market size and forecast, by product
      • 7.4.5.6.South Africa market size and forecast, by end user
      • 7.4.5.7.Saudi Arabia market size and forecast, by technology
      • 7.4.5.8.Saudi Arabia market size and forecast, by product
      • 7.4.5.9.Saudi Arabia market size and forecast, by end user
      • 7.4.5.10.Israel market size and forecast, by technology
      • 7.4.5.11.Israel market size and forecast, by product
      • 7.4.5.12.Israel market size and forecast, by end user
      • 7.4.5.13.Rest of LAMEA market size and forecast, by technology
      • 7.4.5.14.Rest of LAMEA market size and forecast, by product
      • 7.4.5.15.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.Cellex Incorporated
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Key strategic moves and developments
  • 8.3.Cepheid
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Key strategic moves and developments
  • 8.4.F. Hoffmann-La Roche Ltd.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance.
    • 8.4.6.Key strategic moves and developments
  • 8.5.Hologic, Inc.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.Laboratory Corp of America Holdings
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.Mylab Discovery Solutions Pvt. Ltd.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Key strategic moves and developments
  • 8.8.Quest Diagnostics Incorporated
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Seegene Inc.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Key strategic moves and developments
  • 8.10.Thermo Fisher Scientific, Inc.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.APPROVED COVID-19 DIAGNOSTIC PRODUCTS
  • TABLE 02.COVID-19 DIAGNOSTICS MARKET,BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 03.COVID-19 DIAGNOSTICS MARKET,BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 04.COVID-19 DIAGNOSTICS MARKET,BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 05.COVID-19 DIAGNOSTICS MARKET FOR RT PCR, BY REGION, 2020 ($MILLION)
  • TABLE 06.COVID-19 DIAGNOSTICS MARKET FOR RT PCR, BY REGION, 2021 ($MILLION)
  • TABLE 07.COVID-19 DIAGNOSTICS MARKET FOR RT PCR, BY REGION, 2022 ($MILLION)
  • TABLE 08.COVID-19 DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2020 ($MILLION)
  • TABLE 09.COVID-19 DIAGNOSTICS MARKET FOR RT PCR, BY REGION, 2021 ($MILLION)
  • TABLE 10.COVID-19 DIAGNOSTICS MARKET FOR RT PCR, BY REGION, 2022 ($MILLION)
  • TABLE 11.GLOBAL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 12.GLOBAL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 13.GLOBAL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 14.GLOBAL COVID-19 DIAGNOSTICS, FOR PCR KITS, BY REGION, 2020 ($MILLION)
  • TABLE 15.GLOBAL COVID-19 DIAGNOSTICS, FOR PCR KITS, BY REGION, 2021 ($MILLION)
  • TABLE 16.GLOBAL COVID-19 DIAGNOSTICS, FOR PCR KITS, BY REGION, 2022 ($MILLION)
  • TABLE 17.GLOBAL COVID-19 DIAGNOSTICS MARKET FOR IMMUNOASSAY CASSETTES, BY REGION, 2020 ($MILLION)
  • TABLE 18.GLOBAL COVID-19 DIAGNOSTICS, FOR IMMUNOASSAY CASSETTES, BY REGION, 2021 ($MILLION)
  • TABLE 19.GLOBAL COVID-19 DIAGNOSTICS, FOR IMMUNOASSAY CASSETTES, BY REGION, 2022 ($MILLION)
  • TABLE 20.GLOBAL COVID-19 DIAGNOSTICS MARKET FOR POC TEST KITS, BY REGION, 2020-2022 ($MILLION)
  • TABLE 21.GLOBAL COVID-19 DIAGNOSTICS, FOR IMMUNOASSAY CASSETTES, BY REGION, 2021 ($MILLION)
  • TABLE 22.GLOBAL COVID-19 DIAGNOSTICS, FOR IMMUNOASSAY CASSETTES, BY REGION, 2022 ($MILLION)
  • TABLE 23.GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 24.GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 25.GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 26.GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2020 ($MILLION)
  • TABLE 27.GLOBAL COVID-19 DIAGNOSTICS, FOR HOSPITALS, BY REGION, 2021 ($MILLION)
  • TABLE 28.GLOBAL COVID-19 DIAGNOSTICS, FOR HOSPITALS, BY REGION, 2022 ($MILLION)
  • TABLE 29.GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR DIAGNOSIS LABORATORIES, BY REGION, 2020 ($MILLION)
  • TABLE 30.GLOBAL COVID-19 DIAGNOSTICS, FOR DIAGNOSIS LABORATORY, BY REGION, 2021 ($MILLION)
  • TABLE 31.GLOBAL COVID-19 DIAGNOSTICS, FOR DIAGNOSIS LABORATORY, BY REGION, 2022 ($MILLION)
  • TABLE 32.GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PHYSICIAN'S OFFICE AND URGENT CARE CLINICS, BY REGION, 2020 ($MILLION)
  • TABLE 33.GLOBAL COVID-19 DIAGNOSTICS, FOR PHYSICIAN'S OFFICE AND URGENT CARE CLINICS, BY REGION, 2021 ($MILLION)
  • TABLE 34.GLOBAL COVID-19 DIAGNOSTICS, FOR PHYSICIAN'S OFFICE AND URGENT CARE CLINICS, BY REGION, 2022 ($MILLION)
  • TABLE 35.COVID-19 DIAGNOSTICS MARKET, BY REGION, 2020-2022 ($MILLION)
  • TABLE 36.COVID-19 DIAGNOSTICS MARKET, BY REGION, 2020-2022 (NUMBER OF TESTS)
  • TABLE 37.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
  • TABLE 38.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
  • TABLE 39.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
  • TABLE 40.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
  • TABLE 41.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
  • TABLE 42.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (NUMBER OF TESTS)
  • TABLE 43.U.S. COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 44.U.S. COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 45.U.S. COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 46.U.S. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 47.U.S. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 48.U.S. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 49.U.S. COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 50.U.S. COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 51.U.S. COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 52.CANADA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 53.CANADA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 54.CANADA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 55.CANADA. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 56.CANADA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 57.CANADA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 58.CANADA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 59.CANADA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 60.CANADA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 61.MEXICO COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 62.MEXICO COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 63.MEXICO COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 64.MEXICO. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 65.MEXICO COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 66.MEXICO COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 67.MEXICO COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 68.MEXICO COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 69.MEXICO COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 70.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
  • TABLE 71.EUROPE HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
  • TABLE 72.EUROPE HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
  • TABLE 73.EUROPE HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
  • TABLE 74.EUROPE HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
  • TABLE 75.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
  • TABLE 76.FRANCE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 77.FRANCE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 78.FRANCE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 79.FRANCE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 80.FRANCE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 81.FRANCE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 82.FRANCE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 83.FRANCE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 84.FRANCE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 85.UK COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 86.UK COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 87.UK COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 88.UK COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 89.UK COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 90.UK COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 91.UK COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 92.UK COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 93.UK COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 94.GERMANY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 95.GERMANY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 96.GERMANY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 97.GERMANY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 98.GERMANY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 99.GERMANY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 100.GERMANY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 101.GERMANY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 102.GERMANY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 103.SPAIN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 104.SPAIN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 105.SPAIN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 106.SPAIN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 107.SPAIN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 108.SPAIN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 109.SPAIN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 110.SPAIN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 111.SPAIN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 112.ITALY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 113.ITALY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 114.ITALY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 115.ITALY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 116.ITALY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 117.ITALY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 118.ITALY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 119.ITALY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 120.ITALY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 121.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 122.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 123.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 124.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 125.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 126.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 127.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 128.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 129.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 130.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 131.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 132.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 133.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 134.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 135.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 136.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 137.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 138.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 139.CZECH REPUBLICCOVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 140.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 141.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 142.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 143.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 144.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 145.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 146.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 147.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 148.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 149.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 150.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 151.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 152.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 153.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 154.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 155.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 156.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 157.ASIA-PACIFIC HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
  • TABLE 158.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
  • TABLE 159.ASIA-PACIFIC HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
  • TABLE 160.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
  • TABLE 161.ASIA-PACIFIC HEALTHCARE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
  • TABLE 162.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (NUMBER OF TESTS)
  • TABLE 163.JAPAN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 164.JAPAN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 165.JAPAN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 166.JAPAN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 167.JAPAN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 168.JAPAN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 169.JAPAN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 170.JAPAN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 171.JAPAN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 172.CHINA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 173.CHINA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 174.CHINA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 175.CHINA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 176.CHINA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 177.CHINA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 178.CHINA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 179.CHINA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 180.CHINA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 181.INDIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 182.INDIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 183.INDIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 184.INDIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 185.INDIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 186.INDIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 187.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 188.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 189.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 190.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 191.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 192.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 193.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 194.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 195.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 196.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 197.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 198.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 199.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 200.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 201.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 202.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 203.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 204.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 205.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 206.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 207.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 208.THAILAND COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 209.THAILAND COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 210.THAILAND COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 211.THAILAND COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 212.THAILAND COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 213.THAILAND COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 214.THAILAND COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 215.THAILAND COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 216.THAILAND COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 217.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 218.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 219.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 220.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 221.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 222.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 223.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 224.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 225.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 226.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 227.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 228.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 229.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 230.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 231.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 232.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 233.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 234.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 235.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
  • TABLE 236.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
  • TABLE 237.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
  • TABLE 238.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
  • TABLE 239.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
  • TABLE 240.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (NUMBER OF TESTS)
  • TABLE 241.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 242.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 243.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 244.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 245.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 246.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 247.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 248.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 249.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 250.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 251.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 252.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 253.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 254.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 255.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 256.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 257.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 258.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 259.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 260.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 261.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 262.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 263.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 264.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 265.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 266.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 267.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 268.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 269.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 270.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 271.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 272.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 273.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 274.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 275.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 276.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 277.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
  • TABLE 278.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
  • TABLE 279.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
  • TABLE 280.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
  • TABLE 281.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
  • TABLE 282.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
  • TABLE 283.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
  • TABLE 284.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
  • TABLE 285.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
  • TABLE 286.ABBOTT: COMPANY SNAPSHOT
  • TABLE 287.ABBOTT: OERATING SEGMENT
  • TABLE 288.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 289.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 290.CELLEX: COMPANY SNAPSHOT
  • TABLE 291.CELLEX: OPERATING SEGMENTS
  • TABLE 292.CELLEX: PRODUCT PORTFOLIO
  • TABLE 293.CELLEX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 294.CEPHEID: COMPANY SNAPSHOT
  • TABLE 295.CEPHEID: OPERATING BUSINESS SEGMENTS
  • TABLE 296.CEPHEID: PRODUCT PORTFOLIO
  • TABLE 297.ROCHE: COMPANY SNAPSHOT
  • TABLE 298.ROCHE: OPERATING SEGMENTS
  • TABLE 299.ROCHE: PRODUCT PORTFOLIO
  • TABLE 300.HOLOGIC: COMPANY SNAPSHOT
  • TABLE 301.HOLOGIC: OPERATING BUSINESS SEGMENTS
  • TABLE 302.HOLOGIC: PRODUCT PORTFOLIO
  • TABLE 303.LABCORP: COMPANY SNAPSHOT
  • TABLE 304.LABCORP: OPERATING SEGMENTS
  • TABLE 305.LABCORP: PRODUCT PORTFOLIO
  • TABLE 306.MYLAB: COMPANY SNAPSHOT
  • TABLE 307.MYLAB: PRODUCT SEGMENTS
  • TABLE 308.MYLAB: PRODUCT PORTFOLIO
  • TABLE 309.QUEST DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 310.QUEST DIAGNOSTICS: OPERATING BUSINESS SEGMENTS
  • TABLE 311.QUEST: PRODUCT PORTFOLIO
  • TABLE 312.SEEGENE: COMPANY SNAPSHOT
  • TABLE 313.SEEGENE: OPERATING SEGMENTS
  • TABLE 314.SEEGENE: PRODUCT PORTFOLIO
  • TABLE 315.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
  • TABLE 316.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENTS
  • TABLE 317.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL HEALTHCARE COVID-19 DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 02.LOW-TO- MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 03.LOW BARGAINING POWER OF BUYER
  • FIGURE 04.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 05.LOW-TO-MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06.HIGH COMPETITIVE RIVALARY
  • FIGURE 07.DRIVERS AND RESTRAINTS
  • FIGURE 08.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 09.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 01.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 02.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 03.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 04.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 05.HOLOGIC: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 06.HOLOGIC: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 07.HOLOGIC: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 08.LABCORP: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 09.LABCORP: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 10.LABCORP: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 11.QUEST DIAGNOSTICS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 12.QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 13.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 14.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 15.THERMO FISHER SCIENTIFIC. REVENUE SHARE BY REGION, 2019 (%)